The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies

被引：19
|
作者：
Skarbnik, Alan P. [1 ]
Faderl, Stefan [2 ]
机构：
[1] Hackensack Univ, Med Ctr, Div Lymphoma, John Theurer Canc Ctr,Blood & Marrow Transplantat, 92 Second St, Hackensack, NJ 07624 USA
[2] Hackensack Univ, Med Ctr, Div Leukemia, John Theurer Canc Ctr, Hackensack, NJ USA
来源：
THERAPEUTIC ADVANCES IN HEMATOLOGY | 2017年 / 8卷 / 03期
关键词：
chemoimmunotherapy; CLL; FCR; fludarabine; rituximab; PREVIOUSLY UNTREATED PATIENTS; LOW-DOSE FLUDARABINE; INITIAL THERAPY; OPEN-LABEL; AGENT; CHLORAMBUCIL; REGIMEN; FCR; CHEMOTHERAPY; VINCRISTINE;
D O I：
10.1177/2040620716681749
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chemoimmunotherapy (CIT) has become a cornerstone in the treatment of patients with chronic lymphocytic leukemia (CLL). The combination of fludarabine, cyclophosphamide and rituximab (FCR) has emerged as the standard of care for therapy of previously untreated patients with CLL who are younger than 65 years and have no significant comorbidities. In this article, we review the role of FCR in the current treatment paradigm for CLL.
引用
收藏
页数：8
相关论文
共 50 条
  • [1] Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia
    Bosch, Francesc
    Abrisqueta, Pau
    Villamor, Neus
    Jose Terol, Maria
    Gonzalez-Barca, Eva
    Ferra, Christelle
    Gonzalez Diaz, Marcos
    Abella, Eugenia
    Delgado, Julio
    Carbonell, Felix
    Garcia Marco, Jose Antonio
    Escoda, Lourdes
    Ferrer, Secundino
    Monzo, Encarnacion
    Gonzalez, Yolanda
    Estany, Cristina
    Jarque, Isidro
    Salamero, Olga
    Muntanola, Ana
    Montserrat, Emili
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4578 - 4584
  • [2] Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia
    Khan, Yasir
    Lyou, Yung
    El-Masry, Monica
    O'Brien, Susan
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (01) : 31 - 38
  • [3] Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia
    Robak, Tadeusz
    Lech-Maranda, Ewa
    Robak, Pawel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (10) : 1529 - 1543
  • [4] Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia
    Parikh, Sameer A.
    Keating, Michael J.
    O'Brien, Susan
    Wang, Xuemei
    Ferrajoli, Alessandra
    Faderl, Stefan
    Burger, Jan
    Koller, Charles
    Estrov, Zeev
    Badoux, Xavier
    Lerner, Susan
    Wierda, William G.
    BLOOD, 2011, 118 (08) : 2062 - 2068
  • [5] Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia
    Short, Nicholas J.
    Keating, Michael J.
    Wierda, William G.
    Faderl, Stefan
    Ferrajoli, Alessandra
    Estrov, Zeev
    Smith, Susan C.
    O'Brien, Susan M.
    CANCER, 2015, 121 (21) : 3869 - 3876
  • [6] Inferior Outcomes of Fludarabine-Cyclophosphamide-Rituximab Chemotherapy in Korean Chronic Lymphocytic Leukemia Patients with Concurrent Thrombocytopenia and Anemia
    Kim, Tong-Yoon
    Min, Gi-June
    Jeon, Young-Woo
    Yahng, Seung-Ah
    Cho, Seok-Goo
    Lee, Jong-Mi
    Kim, Myungshin
    Eom, Ki-Seong
    BIOMEDICINES, 2025, 13 (01)
  • [7] Fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia: no country for old men?
    Hamblin, Terry J.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (03): : 130 - 131
  • [8] Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies
    Szasz, Robert
    Telek, Bela
    Illes, Arpad
    PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27
  • [9] Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy
    Roeker, Lindsey E.
    Thompson, Meghan
    Mato, Anthony R.
    DRUGS, 2022, 82 (02) : 133 - 143
  • [10] A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia
    Reynolds, Craig
    Di Bella, Nicholas
    Lyons, Roger M.
    Hyman, William
    Richards, Donald A.
    Robbins, Gerald J.
    Vellek, Mark
    Boehm, Kristi A.
    Zhan, Feng
    Asmar, Lina
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1232 - 1240
12345